Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06169046

A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy (BetaSBMA)

A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Sponsor: Gianni Soraru

Conditions Spinal and Bulbar Muscular Atrophy

Interventions Clenbuterol Placebo

Updated 5 times since 2024 Last updated: Apr 12, 2024 Started: Apr 13, 2024 Primary completion: Jun 30, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06169046, this PHASE2 trial focuses on Spinal and Bulbar Muscular Atrophy and remains actively recruiting participants. Sponsored by Gianni Soraru, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gianni Soraru
Mario Negri Institute for Pharmacological Research

Data source: University Hospital Padova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Padua, Italy